Pfizer Inc (PFE)

31.19
NYSE : Health Care
Prev Close 31.19
Day Low/High 0.00 / 0.00
52 Wk Low/High 28.25 / 37.39
Avg Volume 24.92M
Exchange NYSE
Shares Outstanding 6.07B
Market Cap 191.52B
EPS 1.10
P/E Ratio 15.10
Div & Yield 1.20 (3.80%)

Latest News

5 Things You Must Know Before the Market Opens Wednesday

5 Things You Must Know Before the Market Opens Wednesday

U.S. stock futures rise following another record close for the Dow Jones Industrial Average; Pfizer is fined $107 million for hiking the price of an epilepsy drug.

Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At Healthcare Conference

Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At Healthcare Conference

Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Ian Read, Chairman and CEO, at the Guggenheim 4 th Annual Boston Healthcare Conference on Tuesday, December 13, 2016 at...

Pfizer And Avillion Announce Positive Top-Line Results For Phase 3 BFORE Study Of BOSULIF For First-Line Treatment Of Philadelphia Chromosome Positive Chronic Myeloid Leukemia

Pfizer And Avillion Announce Positive Top-Line Results For Phase 3 BFORE Study Of BOSULIF For First-Line Treatment Of Philadelphia Chromosome Positive Chronic Myeloid Leukemia

Today, Pfizer Inc. and its partner Avillion LLP announced results from the Phase 3 BFORE ( B osutinib trial in F irst line chr O nic myelogenous leukemia t RE atment) trial demonstrating superiority of...

Spark's Hemophilia Gene Therapy Remains Effective Despite Immune Reactions

Spark's Hemophilia Gene Therapy Remains Effective Despite Immune Reactions

Spark believes temporary treatment with steroids can arrest the immune response before it causes factor IX levels to fall to a point where bleeding risk becomes a problem.

New Phase 2 Results Show Investigational Compound Glasdegib Improved Overall Survival In Acute Myeloid Leukemia And High-Risk Myelodysplastic Syndrome

New Phase 2 Results Show Investigational Compound Glasdegib Improved Overall Survival In Acute Myeloid Leukemia And High-Risk Myelodysplastic Syndrome

Today, Pfizer Inc. (NYSE:PFE) announced new data from a randomized Phase 2 study of glasdegib (PF-04449913), an oral, smoothened (SMO) inhibitor, showing the addition of glasdegib to low-dose cytarabine (LDAC) significantly...

Morgan Stanley Wealth Management: Chevron, Pfizer May be Big Winners in 2017

Morgan Stanley Wealth Management: Chevron, Pfizer May be Big Winners in 2017

Chevron and Pfizer may not just be big yielders in 2017, but big winners too, says Morgan Stanley's Dan Skelly.

IBM and Pfizer to Accelerate Immuno-oncology Research with Watson for Drug Discovery

IBM and Pfizer to Accelerate Immuno-oncology Research with Watson for Drug Discovery

Collaboration combines IBM Watson's cognitive computing capabilities with Pfizer's scientific knowledge to help scientists generate meaningful insights

Pfizer Invites Public To View And Listen To Webcast Of Pfizer Presentation At Healthcare Conference

Pfizer Invites Public To View And Listen To Webcast Of Pfizer Presentation At Healthcare Conference

Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Mikael Dolsten, President, Worldwide Research and Development, at the Citi 2016 Global Healthcare Conference on...

LYRICA® (pregabalin) Phase 3 Trial In Pediatric Epilepsy Meets Primary Endpoint

LYRICA® (pregabalin) Phase 3 Trial In Pediatric Epilepsy Meets Primary Endpoint

Pfizer Inc. (NYSE:PFE) announced today positive top-line results of a study that evaluated the use of LYRICA® (pregabalin) Capsules CV and Oral Solution CV as adjunctive therapy for pediatric epilepsy patients four to...

Omnicell's Performance Center Integrates With Hospira's Infusion Pump Software

Omnicell's Performance Center Integrates With Hospira's Infusion Pump Software

New Interoperability Is Designed to Streamline Clinical Workflow

The Most Admired Corporate Dealmakers in a Record Year

The Most Admired Corporate Dealmakers in a Record Year

In a record year for acquisitions, 18 companies from across the spectrum were singled out by M&A professionals for doing deals that got results.

10 Undervalued High-Yield Dividend Stocks Worth Buying Today

10 Undervalued High-Yield Dividend Stocks Worth Buying Today

Each dividend stock scores well for safety and has a historically high dividend yield.

Pfizer Announces Positive Top-Line Results From The Pivotal Comparative REFLECTIONS B3271002 Study For PF-05280014, A Potential Biosimilar To Herceptin®1 (trastuzumab)

Pfizer Announces Positive Top-Line Results From The Pivotal Comparative REFLECTIONS B3271002 Study For PF-05280014, A Potential Biosimilar To Herceptin®1 (trastuzumab)

Pfizer Inc. (NYSE:PFE) today announced that the pivotal REFLECTIONS B3271002 study, a comparative safety and efficacy study of PF-05280014 versus Herceptin® (trastuzumab), met its primary endpoint.

In Case You Missed It Tuesday: Self-Driving Cars, Soy, Slumping Commodities Take Markets for a Ride

In Case You Missed It Tuesday: Self-Driving Cars, Soy, Slumping Commodities Take Markets for a Ride

A Brazilian plane crash near Medellín on Monday included 21 journalists, among the largest number of media personnel to die in any one incident.

Closing Bell: Crude Tumbles to Two-Week Low; U.S. Stocks Inch Higher

Closing Bell: Crude Tumbles to Two-Week Low; U.S. Stocks Inch Higher

Stocks climbed as evidence of an economy on the mend overshadowed a slump in crude oil prices.

Stocks Stop Short of Records as Crude Collapses to Two-Week Low

Stocks Stop Short of Records as Crude Collapses to Two-Week Low

Wall Street ended just shy of records on Tuesday as a collapse in crude oil prices limited upward momentum.

Pfizer Upgraded at Barclays

Pfizer Upgraded at Barclays

Shares of Pfizer were slightly higher on Tuesday as Barclays upgraded its rating to Overweight from Equal Weight

Stocks Climb as Solid U.S. Economic Growth Overshadows Oil's Tumble

Stocks Climb as Solid U.S. Economic Growth Overshadows Oil's Tumble

Stocks climb on Tuesday as evidence of an economy on the mend overshadows a slump in crude oil prices.

Cramer: Rally Isn't Because Trump's Coming In but Because Fed's Going Out

Cramer: Rally Isn't Because Trump's Coming In but Because Fed's Going Out

Market should still be able to breathe once central-bank prop is removed.

Pfizer (PFE) Stock Rating Upgraded at Barclays

Pfizer (PFE) Stock Rating Upgraded at Barclays

Pfizer's (PFE) stock rating at Barclays was upgraded to 'overweight' earlier today.

S&P 500 Shakes Off Oil Slump to Post Gains

S&P 500 Shakes Off Oil Slump to Post Gains

Stocks move higher on Tuesday morning, shaking off earlier losses driven by a slump in crude oil.

Pfizer: Be Happy With the Dividend for Now

Pfizer: Be Happy With the Dividend for Now

A new period of accumulation and sideways price action is likely needed before any upside movess.

Stock Futures Turn Mixed as U.S. Economy Grows, Oil Prices Slump

Stock Futures Turn Mixed as U.S. Economy Grows, Oil Prices Slump

Stock futures hold higher on Tuesday morning, unperturbed by a sharp decline in crude oil prices, as the U.S. economy grows at a faster-than-expected pace over the third quarter.

Analysts' Actions -- Goldman Sachs, Johnson & Johnson, Pfizer and More

Analysts' Actions -- Goldman Sachs, Johnson & Johnson, Pfizer and More

Here are Tuesday's top research calls, including an upgrade for Pfizer, and downgrades for Goldman Sachs, Johnson & Johnson, Delphi and Darden Restaurants.

Some 'January Effect' Stock Picks

Some 'January Effect' Stock Picks

Small-caps could also benefit from abating tax-loss selling.

Merck Raises Dividend

We favor AbbVie and Pfizer in pharma sector.

Anthony J. Maddaluna, Executive Vice President And President Of Pfizer Global Supply To Retire

Anthony J. Maddaluna, Executive Vice President And President Of Pfizer Global Supply To Retire

Pfizer Inc. (NYSE:PFE) today announced that Anthony J.